Results 51 to 60 of about 25,486 (236)

Perspectives and practices of ototoxicity monitoring

South African Journal of Communication Disorders, 2020
Background: Treatment of cancer with cisplatin can result in hearing loss. Given the increasing burden of cancer in Africa, appropriate and timely identification, intervention and management of hearing loss in affected patients is of paramount importance.
Jessica Paken, Cyril D. Govender, Mershen Pillay, Vikash Sewram   +3 more
doaj   +1 more source

Cisplatin ototoxicity mechanism and antagonistic intervention strategy: a scope review

Frontiers in Cellular Neuroscience, 2023
Cisplatin is a first-line chemotherapeutic agent in the treatment of malignant tumors with remarkable clinical effects and low cost. However, the ototoxicity and neurotoxicity of cisplatin greatly limit its clinical application.
Yingru Li, Yingru Li, Yingru Li, Tianyang Zhang, Tianyang Zhang, Tianyang Zhang, Qiang Song, Qiang Song, Qiang Song, Dekun Gao, Dekun Gao, Dekun Gao, Yue Li, Yue Li, Yue Li, Huiqun Jie, Huiqun Jie, Huiqun Jie, Ping Huang, Ping Huang, Ping Huang, Guiliang Zheng, Guiliang Zheng, Guiliang Zheng, Jun Yang, Jun Yang, Jun Yang, Jingchun He, Jingchun He, Jingchun He   +29 more
doaj   +1 more source

Cancer therapy‐induced ototoxicity: Current challenges and emerging management strategies

Animal Models and Experimental Medicine, EarlyView.
This review comprehensively examines the key risk factors for cancer therapy‐induced ototoxicity, including cumulative drug dose, genetic susceptibility, and combined treatment regimens. It highlights current challenges in ototoxicity monitoring, such as insufficient timeliness and limited clinical adoption, and advocates for standardized auditory ...
Yuqi Huang, Baoying Xu, Xinru Chen, Yu Chen, Dehong Yu   +4 more
wiley   +1 more source

Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis [PDF]

, 2017
Background: The prolonged use of injectable agents in an MDR-TB regimen is recommended by the WHO despite association with ototoxicity and nephrotoxicity.Objective: We undertook this study to look at the relative adverse effects of capreomycin and ...
Ahuja, Amber Arnold, American Speech-Language-Hearing Association, Angela Loyse, Aquinas, Bardien, Bindu, British Society of Audiology, Caminero, Donomae, Duggal, Graham S. Cooke, Harris, Holmes, Hutchin, Irina Chis Ster, Kass, Kranzer, Marc Lipman, Martin Dedicoat, Melchionda, Miller, Modongo, Nunn, Onn Min Kon, Ramma, Sagwa, Sagwa, Seddon, Seddon, Shean, Shin, Sterne, Sturdy, Thomas S. Harrison, Tsukamura, U.S. Department of Health and Human Services, van Altena, World Health Organization, World Health Organization, World Health Organization, World Health Organization, Wu   +42 more
core   +1 more source

Systematic review and scoring‐based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and children

British Journal of Clinical Pharmacology, EarlyView.
This systematic review identified 112 population pharmacokinetic models of vancomycin in neonates and children. To support rational model selection for model‐informed precision, we developed and applied expert‐driven, transparent criteria that integrate both methodological rigour and clinical relevance.
Zoë Vander Elst, Pieter‐Jan Spiessens, Dorian Vanneste, Nada Dia, Matthias Gijsen, Isabel Spriet, Karel Allegaert, Erwin Dreesen, Anne Smits   +8 more
wiley   +1 more source

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Scientific Reports
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and
Ning Wang, Haijun Wang, Ying Chen, Yanfeng Wang   +3 more
doaj   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Oncologists' views on ototoxicity monitoring in head and neck cancer patients: A South Indian qualitative study.

PLoS ONE
AimThe perspectives and practices of healthcare professionals regarding ototoxicity in individuals with head and neck cancers are important for the implementation of ototoxicity monitoring. The current study aims to explore the oncologist's awareness and
Varsha Shankar, Jayashree Seethapathy, Satish Srinivas, Raghu Nandhan, Prasanna Kumar Saravanam   +4 more
doaj   +1 more source

Current Strategies to Combat Cisplatin-Induced Ototoxicity

Frontiers in Pharmacology, 2020
Cisplatin is widely used for the treatment of a number of solid malignant tumors. However, ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for this toxicity has not been fully elucidated.
Dehong Yu, Dehong Yu, Dehong Yu, Jiayi Gu, Jiayi Gu, Jiayi Gu, Yuming Chen, Yuming Chen, Yuming Chen, Wen Kang, Wen Kang, Wen Kang, Xueling Wang, Xueling Wang, Xueling Wang, Hao Wu, Hao Wu, Hao Wu   +17 more
doaj   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source